organization · Reporting owner

Arix Bioscience plc

Disclosed activity across 3 companies

Tapewire entity: 146164
SEC CIK: 0001700449

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Harpoon Therapeutics, Inc.HARP · Entity 11424	10% owner	May 27, 2020	May 29, 2020
LogicBio Therapeutics, Inc.LOGC · Entity 122292	10% owner	July 16, 2020	October 05, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Harpoon Therapeutics, Inc.

Report date May 27, 2020 · Filed May 29, 2020

Jointly reported with Arix Bioscience Holdings Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	IndirectSee Footnote	2,193,704	Last balance in matching sequence After 2020-05-28 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-05-27 · Sale · Disposed 12,064 · Balance 2,560,295 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $22.00 to $24.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Row 2 · 2020-05-28 · Sale · Disposed 366,591 · Balance 2,193,704 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $22.00 to $24.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.

F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

LogicBio Therapeutics, Inc.

Report date July 16, 2020 · Filed October 05, 2020

Jointly reported with Arix Bioscience Holdings Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	IndirectSee footnote	2,381,436	Last balance in matching sequence After 2020-09-28 transaction · row 10 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 10 source rows Row 1 · 2020-07-16 · Sale · Disposed 16,332 · Balance 2,962,691 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 2 · 2020-07-17 · Sale · Disposed 31,101 · Balance 2,931,590 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 3 · 2020-07-20 · Sale · Disposed 36,983 · Balance 2,894,607 F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 4 · 2020-07-22 · Sale · Disposed 22,651 · Balance 2,871,956 F5: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 5 · 2020-07-29 · Sale · Disposed 2,709 · Balance 2,869,247 F6: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 6 · 2020-08-12 · Sale · Disposed 1,335 · Balance 2,867,912 F7: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 7 · 2020-08-13 · Sale · Disposed 159 · Balance 2,867,753 F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 8 · 2020-09-24 · Sale · Disposed 38,514 · Balance 2,829,239 F8: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 9 · 2020-09-25 · Sale · Disposed 174,219 · Balance 2,655,020 F9: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Row 10 · 2020-09-28 · Sale · Disposed 273,584 · Balance 2,381,436 F10: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.

F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.

F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F5: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F6: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F7: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F8: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F9: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

F10: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Enliven Therapeutics, Inc.

Report date March 16, 2020 · Filed March 16, 2020

Jointly reported with Arix Bioscience Holdings Ltd

Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy entities affiliated with Arix Bioscience plc	1,554,558	Last balance in matching sequence After 2020-03-16 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-03-16 · Conversion · Acquired 1,367,058 · Balance 1,367,058 F1: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Row 2 · 2020-03-16 · Purchase · Acquired 187,500 · Balance 1,554,558 F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy entities affiliated with Arix Bioscience plc	0	Reported balance After 2020-03-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-03-16 · Conversion · Disposed 8,611,110 · Balance 0 F1: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 28, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	273,584	$7.54	$2,061,865.82	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 10 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,381,436 F10 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
September 25, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	174,219	$7.08	$1,232,947.86	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 9 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,655,020 F9 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
September 24, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	38,514	$7.63	$293,823.31	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 8 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,829,239 F8 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
August 13, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	159	$8.75	$1,391.25	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 7 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,867,753 F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
August 12, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	1,335	$8.79	$11,734.65	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 6 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,867,912 F7 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
July 29, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	2,709	$8.78	$23,787.73	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 5 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,869,247 F6 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
July 22, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	22,651	$9.00	$203,949.60	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 4 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,871,956 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
July 20, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	36,983	$9.25	$342,055.77	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,894,607 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
July 17, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	31,101	$9.24	$287,373.24	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,931,590 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
July 16, 2020 Filed Oct 5, 2020 17:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	SaleCommon stock	16,332	$8.56	$139,785.59	Disclosure SEC source: 0000899243-20-027297 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,962,691 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Read SEC document
May 28, 2020 Filed May 29, 2020 16:32 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	366,591	$21.33	$7,820,925.71	Disclosure SEC source: 0000899243-20-014559 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,193,704 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
May 27, 2020 Filed May 29, 2020 16:32 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	12,064	$22.39	$270,144.33	Disclosure SEC source: 0000899243-20-014559 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,560,295 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $22.00 to $24.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	ConversionSeries B Preferred Stock · Derivative	8,611,110	$0.00	$0.00	Disclosure SEC source: 0000899243-20-008474 · doc4.xml · derivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Arix Bioscience plc Disclosed balance after: 0 Underlying: Common Stock · 1,367,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	PurchaseCommon Stock	187,500	$16.00	$3,000,000.00	Disclosure SEC source: 0000899243-20-008474 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Arix Bioscience plc Disclosed balance after: 1,554,558 F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
March 16, 2020 Filed Mar 16, 2020 17:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	ConversionCommon Stock	1,367,058	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-008474 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By entities affiliated with Arix Bioscience plc Disclosed balance after: 1,367,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 17, 2019 Filed Dec 17, 2019 19:20 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	12,476	$16.83	$209,968.58	Disclosure SEC source: 0000899243-19-029473 · doc4.xml · nonDerivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,572,359 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 16, 2019 Filed Dec 17, 2019 19:20 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	13,080	$17.02	$222,680.46	Disclosure SEC source: 0000899243-19-029473 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,584,835 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.28 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 13, 2019 Filed Dec 17, 2019 19:20 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	11,002	$17.21	$189,341.12	Disclosure SEC source: 0000899243-19-029473 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,597,915 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.68 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 10, 2019 Filed Dec 10, 2019 19:27 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	131,696	$16.91	$2,227,018.87	Disclosure SEC source: 0000899243-19-028848 · doc4.xml · nonDerivative · entry 4 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,608,917 F1 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 09, 2019 Filed Dec 10, 2019 19:27 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	77,316	$18.12	$1,400,664.39	Disclosure SEC source: 0000899243-19-028848 · doc4.xml · nonDerivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,740,613 F1 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 09, 2019 Filed Dec 10, 2019 19:27 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	26,438	$18.30	$483,781.03	Disclosure SEC source: 0000899243-19-028848 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,817,929 F1 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
December 06, 2019 Filed Dec 10, 2019 19:27 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon stock	47,752	$19.15	$914,221.59	Disclosure SEC source: 0000899243-19-028848 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,844,367 F1 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
February 12, 2019 Filed Feb 14, 2019 18:01 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionSeries C Convertible Preferred Stock · Derivative	742,850	$0.00	$0.00	Disclosure SEC source: 0000899243-19-003683 · doc4.xml · derivative · entry 4 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 742,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
February 12, 2019 Filed Feb 14, 2019 18:01 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionSeries B Convertible Preferred Stock · Derivative	1,720,698	$0.00	$0.00	Disclosure SEC source: 0000899243-19-003683 · doc4.xml · derivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,720,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
February 12, 2019 Filed Feb 14, 2019 18:01 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	PurchaseCommon stock	428,571	$14.00	$5,999,994.00	Disclosure SEC source: 0000899243-19-003683 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,892,119 F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
February 12, 2019 Filed Feb 14, 2019 18:01 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionCommon stock	2,463,548	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-003683 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,463,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering. F2 · balance_after: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
October 23, 2018 Filed Oct 26, 2018 09:29 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	ConversionSeries B Preferred Stock · Derivative	4,352,775	$0.00	$0.00	Disclosure SEC source: 0000899243-18-027509 · doc4.xml · derivative · entry 3 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,279,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the "Issuer") common stock effective upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the "Issuer") common stock effective upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the "Issuer") common stock effective upon closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
October 23, 2018 Filed Oct 26, 2018 09:29 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	PurchaseCommon stock	700,000	$10.00	$7,000,000.00	Disclosure SEC source: 0000899243-18-027509 · doc4.xml · nonDerivative · entry 2 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,979,023 F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document
October 23, 2018 Filed Oct 26, 2018 09:29 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	ConversionCommon stock	2,279,023	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-027509 · doc4.xml · nonDerivative · entry 1 Arix Bioscience plc · CIK 0001700449 · 10% owner Arix Bioscience Holdings Ltd · CIK 0001756884 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,279,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the "Issuer") common stock effective upon closing of the Issuer's initial public offering. F2 · balance_after: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. F2 · ownership.nature: These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.